A biotech seeking IPO riches delayed revealing patient deaths tied to immunotherapy

Retrieved on: 2018-03-04 00:52:30

Tags for this article:

Feuerstein

Adam Feuerstein

Writers

American writers

Journalists

Click the tags to see associated articles and topics

A biotech seeking IPO riches delayed revealing patient deaths tied to immunotherapy. View article details on hiswai:

Excerpt

<div>rivate biotechs are like Instagram posts. The glossy, successful image they choose to share can hide darker truths. So it's been with Unum Therapeutics, a buzzy T-cell cancer immunotherapy startup backed by a roster of powerful investors, including the A-list VC firm <b>Atlas Venture</b>. On Friday, Unum filed ...</div>

Article found on:

View Original Article